Overview

Hepatic Xenetix-CT Perfusion

Status:
Completed

Trial end date:
2014-10-01

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to prospectively determine the diagnostic value of Xenetix-CT perfusion for the discrimination between well-differentiated hepatocellular carcinomas (HCC) and poorly/moderately differentiated HCC, in histo-pathologically proven HCC, and with the aim to cover the entire liver.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Guerbet

Criteria

Inclusion Criteria:

- Subjects diagnosed for HCC and planned for surgery (lobectomy or transplantation)
within a timeframe of 30 days between first imaging procedure used for the study and
surgery.

Exclusion Criteria:

- Subjects who have undergone prior TACE (TransArterial Chemo Embolization), prior RFA
(Radio Frequency Ablation) or prior SIRT (Selected Internal Radio Therapy) within one
year before inclusion.